Home>Topics>Stocks>Vertex Pharmaceuticals

Vertex Pharmaceuticals VRTX

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 1-Royalty Pharma buys royalties on Vertex Pharma drugs for $3.3 bln

      Headlines

      Wed, 19 Nov 2014

      Nov 19 (Reuters) - Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash.

    2. Royalty Pharma buys royalties on Vertex Pharma drugs for $3.3 bln

      Headlines

      Wed, 19 Nov 2014

      Nov 19 (Reuters) - Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash.

    3. Morningstar / portfolio / xray / stock intersector

      Commentary

      Tue, 18 Nov 2014

      surprised that my second largest stock holding is UNP(2.87%) by my FSRFX fund. ACT(2.7%), UPS(2.27%) and VRTX (1.85%) round out the top five. I have a number of my own spreadsheets with charts, but this is one thing that would be

    4. A Favorable Prognosis for This Pharma Stock

      Video Reports

      Thu, 18 Sep 2014

      Stefan Quenneville: We think [TICKER: VRTX ] Vertex Pharmaceuticals ( VRTX ) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant

      Vertex Pharmaceuticals VRTX found at 0:04

      Stefan Quenneville: We VRTX Vertex Pharmaceuticals ( VRTX ) has a positive moat trend because its recent clinical success in cystic fibrosis positions it as a dominant player in this very
    5. Managing Expectations, Part II

      Headlines

      Tue, 19 Aug 2014

      which may face some tough competition if Albuferon receives Food and Drug Administration approval. We still think Vertex's VRTX Phase II telaprevir holds the most promise among hepatitis C drugs in development. Human Genome Sciences and partner Novartis

    6. Reinvent Your Practice: Alternatives to Traditional Succession Planning

      Headlines

      Fri, 25 Apr 2014

      Worldwide UTIW Vertex Pharmaceuticals VRTX Walt Disney DIS ..... UTi Worldwide Vertex Pharmaceuticals Economic Moat ..... thinks Vertex's VRTX expertise in chronic ..... Analyst Report: Vertex Pharmaceuticals Walt Disney

    7. How Did Facebook End Up in the S&P 500?

      Headlines

      Tue, 17 Dec 2013

      Michael Kors Holdings KORS, Delta Air Lines DAL, News Corp NWSA, oil-services company Transocean RIG, and Vertex Pharmaceuticals VRTX . Meanwhile, those leaving the index included Dell, Sprint S, J.C. Penney JCP, Dean Foods DF, and

    8. ClearBridge Fund Prepared for Extended Rally

      Video Reports

      Fri, 11 Oct 2013

      new oral multiple sclerosis compound. [TICKER:AMGN] Amgen as well, which recently announced an acquisition of [TICKER: VRTX ] Onyx Pharmaceuticals, has been strong from an earnings perspective and a stock perspective. And a name like Vertex, which

      VRTX found at 1:09

      oral multiple sclerosis compound. [TICKER:AMGN] Amgen as well, which recently announced an acquisition of [TICKER: VRTX ] Onyx Pharmaceuticals, has been strong from an earnings perspective and a stock perspective. And a name like Vertex, which has been a
    9. Gilead Sciences Carving Out a Wider Moat

      Headlines

      Thu, 8 Aug 2013

      weeks of therapy, with few side effects. For perspective, the current standard of care (with drugs like Vertex Pharmaceuticals ' VRTX Incivek) results in cure rates of around 70% for most previously untreated patients, treatment typically

    10. Vertex's Kalydeco Sees Strong Sales and Clinical Data, In Line With Our Expectations

      Commentary

      Mon, 29 Jul 2013

      Vertex VRTX reported second-quarter results that were in line with our expectations, and we're not making any changes to our $89-per

    « Prev12345Next »
    Content Partners